VBIO rises after Valion Bio highlights oral Entolimod formulation milestone

Valion Bio, Inc. (VBIO) is up 18.0% today. Here is some analysis on what might have caused this price movement. ([stocktitan.net](https://www.stocktitan.net/news/VBIO/valion-bio-and-shear-kershman-laboratories-successfully-formulate-3j4k3f35sfg2.html))

Analysis: The most likely catalyst is Valion Bio’s September 30 announcement that it completed formulation work on an oral mucosal version of Entolimod with Shear Kershman Laboratories, giving investors a fresh development milestone and a possible new delivery path beyond injection. The rally may also be getting support from the company’s recent Nasdaq compliance update and other late-September corporate changes, which together improved the near-term narrative around listing risk and execution. ([stocktitan.net](https://www.stocktitan.net/news/VBIO/valion-bio-and-shear-kershman-laboratories-successfully-formulate-3j4k3f35sfg2.html))

Details:

Valion Bio said it successfully completed formulation work for a BioViscid-based oral mucosal version of Entolimod, its investigational biologic for radiation injury. ([stocktitan.net](https://www.stocktitan.net/news/VBIO/valion-bio-and-shear-kershman-laboratories-successfully-formulate-3j4k3f35sfg2.html))

The company described the program as a potential needle-free delivery route, with the next step focused on whether oral mucosal dosing produces measurable systemic exposure and a usable pharmacokinetic profile. ([stocktitan.net](https://www.stocktitan.net/news/VBIO/valion-bio-and-shear-kershman-laboratories-successfully-formulate-3j4k3f35sfg2.html))

Valion previously disclosed in its quarterly report that it had engaged Shear Kershman Labs in April 2026 to develop a heat-stable oral transmucosal formulation, so the latest update appears to mark progress on an existing program rather than a brand-new initiative. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1787740/000143774926028069/vbio20260630c_10q.htm?utm_source=openai))

The stock’s reaction may have been amplified by the company’s very small share base after its 1-for-25 reverse split and by its recent notice that it regained compliance with Nasdaq’s minimum bid price rule. ([stocktitan.net](https://www.stocktitan.net/sec-filings/VBIO/))

Sources:

Valion Bio press release, SEC, Nasdaq

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$VBIO Hedge Fund Activity

We have seen 6 institutional investors add shares of $VBIO stock to their portfolio, and 3 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MURCHINSON LTD. added 115,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $59,788
GEODE CAPITAL MANAGEMENT, LLC removed 68,444 shares (-77.9%) from their portfolio in Q2 2026, for an estimated $35,584
VIRTU FINANCIAL LLC added 39,225 shares (+inf%) to their portfolio in Q2 2026, for an estimated $20,393
HRT FINANCIAL LP removed 30,957 shares (-73.0%) from their portfolio in Q2 2026, for an estimated $16,094
XTX TOPCO LTD removed 10,506 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $5,462
TWO SIGMA SECURITIES, LLC added 10,162 shares (+inf%) to their portfolio in Q2 2026, for an estimated $5,283
UBS GROUP AG added 8,728 shares (+368.9%) to their portfolio in Q2 2026, for an estimated $4,537

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.